File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Treatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations

TitleTreatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations
Authors
Keywordschildren and adolescents
refractory and relapsed non-Hodgkin lymphoma
stem cell transplant
Issue Date2021
PublisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/
Citation
Cancers, 2021, v. 13 n. 9, p. article no. 2075 How to Cite?
AbstractDespite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.
Persistent Identifierhttp://hdl.handle.net/10722/306727
ISSN
2018 Impact Factor: 6.162
2020 SCImago Journal Rankings: 1.818
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorBurkhardt, B-
dc.contributor.authorTaj, M-
dc.contributor.authorGarnier, N-
dc.contributor.authorMinard-Colin, V-
dc.contributor.authorHazar, V-
dc.contributor.authorMellgren, K-
dc.contributor.authorOsumi, T-
dc.contributor.authorFedorova, A-
dc.contributor.authorMyakova, N-
dc.contributor.authorVerdu-Amoros, J-
dc.contributor.authorAndres, M-
dc.contributor.authorKabickova, E-
dc.contributor.authorAttarbaschi, A-
dc.contributor.authorChiang, AKS-
dc.contributor.authorBubanska, E-
dc.contributor.authorDonska, S-
dc.contributor.authorHjalgrim, LL-
dc.contributor.authorWachowiak, J-
dc.contributor.authorPieczonka, A-
dc.contributor.authorUyttebroeck, A-
dc.contributor.authorLazic, J-
dc.contributor.authorLoeffen, J-
dc.contributor.authorBuechner , J-
dc.contributor.authorNiggli, F-
dc.contributor.authorCsoka, M-
dc.contributor.authorKrivan, G-
dc.contributor.authorPalma, J-
dc.contributor.authorBurke, GAA-
dc.contributor.authorBeishuizen, A-
dc.contributor.authorKoeppen, K-
dc.contributor.authorMueller, S-
dc.contributor.authorHerbrueggen, H-
dc.contributor.authorWoessmann, W-
dc.contributor.authorZimmermann, M-
dc.contributor.authorBalduzzi, A-
dc.contributor.authorPillon, M-
dc.date.accessioned2021-10-22T07:38:44Z-
dc.date.available2021-10-22T07:38:44Z-
dc.date.issued2021-
dc.identifier.citationCancers, 2021, v. 13 n. 9, p. article no. 2075-
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/10722/306727-
dc.description.abstractDespite poor survival, controversies remain in the treatment for refractory or relapsed pediatric non-Hodgkin lymphoma (r/r NHL). The current project aimed to collect international experience on the re-induction treatment of r/r NHL, hematopoietic stem cell transplantation (HSCT), risk factors associated with outcome, and to suggest treatment recommendations. Inclusion criteria were (i) refractory disease, disease progression or relapse of any NHL subtype except anaplastic large cell lymphoma, (ii) age < 18 years at initial diagnosis, (iii) diagnosis in/after January 2000. Data from 639 eligible patients were evaluable. The eight-year probability of overall survival was 34 ± 2% with highly significant differences according to NHL subtypes: 28 ± 3% for 254 Burkitt lymphoma/leukemia, 50 ± 6% for 98 diffuse large B-cell lymphomas, 57 ± 8% for 41 primary mediastinal large B-cell lymphomas, 27 ± 3% for 177 T-lymphoblastic lymphomas, 52 ± 10% for 34 precursor-B-cell lymphoblastic lymphomas and 30 ± 9% for 35 patients with rare NHL subtypes. Subtype-specific factors associated with survival and treatment recommendations are suggested. There were no survivors without HSCT, except in few very small subgroups. Conclusions: There is an urgent need to further improve survival in r/r NHL. The current study provides the largest real-world series, which underlines the role of HSCT and suggests treatment recommendations.-
dc.languageeng-
dc.publisherMDPI AG. The Journal's web site is located at http://www.mdpi.com/journal/cancers/-
dc.relation.ispartofCancers-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectchildren and adolescents-
dc.subjectrefractory and relapsed non-Hodgkin lymphoma-
dc.subjectstem cell transplant-
dc.titleTreatment and Outcome Analysis of 639 Relapsed Non-Hodgkin Lymphomas in Children and Adolescents and Resulting Treatment Recommendations-
dc.typeArticle-
dc.identifier.emailChiang, AKS: chiangak@hku.hk-
dc.identifier.authorityChiang, AKS=rp00403-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/cancers13092075-
dc.identifier.pmid33923026-
dc.identifier.pmcidPMC8123268-
dc.identifier.scopuseid_2-s2.0-85104606116-
dc.identifier.hkuros328942-
dc.identifier.volume13-
dc.identifier.issue9-
dc.identifier.spagearticle no. 2075-
dc.identifier.epagearticle no. 2075-
dc.identifier.isiWOS:000649881100001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats